SCHEMBL24716652

SCHEMBL24716652

COCOc1ccc(C=O)c2cccnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.54
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
HSP90AA1 P07900 1/20 0.54
IDO1 P14902 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CCR1 P32246 1/20 0.44
CCR5 P51681 1/20 0.44
CCR8 P51685 1/20 0.44
PKM P14618 1/20 0.40
ERN1 O75460 2/20 0.39
ALOX12 P18054 2/20 0.39
CYP3A4 P08684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.38
ALDH1A1 P00352 3/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30626618 1.00 KDM4E (0.54) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL29126398 0.86 PKM (0.38) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL3156151 0.85 KMT2A (0.59) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL8346630 0.79 NPC1 (0.55) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL27974941 0.78 APP (0.47) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL24716650 0.78 MEN1 (0.49) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL8348622 0.77 KDM4E (0.50) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL23715389 0.75 KMT2A (0.59) KDM4ENPC1RAB9AKMT2AMEN1
SCHEMBL27190066 0.74 POLB (0.38) KDM4ENPC1RAB9ANPSR1PKM
SCHEMBL8973912 0.74 PTPN1 (0.40) KDM4ENPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4623914-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-10-01 EP disclosed
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-07-25 US disclosed
CN-118059101-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2024-05-24 CN disclosed
EP-4349815-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2024-04-10 EP disclosed
CN-117043141-A 7-nitro-8-hydroxyquinoline derivative, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2023-11-10 CN disclosed
WO-2022253152-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF CYP3A7, UGT1A7, UGT2B7 KDM4E 2921/4885NPC1 373/4885RAB9A 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.